Search results for " Large"

showing 10 items of 392 documents

A Search for Heavy Stable and Long-Lived Squarks and Sleptons in $e^+ e^-$ Collisions at Energies from 130 to 183 GeV

1998

A search for stable and long-lived heavy charged particles used the data taken by the DELPHI experiment at energies from 130 to 183 GeV. The Cherenkov light detected in the Ring Imaging Cherenkov Detector and the ionization loss measured in the Time Projection Chamber identify heavy particles from masses of 2 to nearly 89 GeV/c$^2$. Upper limits are given on the production cross-section and masses of sleptons, free squarks with a charge of $q = \pm 2/3e$ and hadronizing squarks. A search for stable and long-lived heavy charged particles used the data taken by the DELPHI experiment at energies from 130 to 183 GeV. The Cherenkov light detected in the Ring Imaging Cherenkov Detector and the io…

Nuclear and High Energy PhysicsParticle physicsPhysics::Instrumentation and DetectorsFOS: Physical sciences01 natural sciencesRing-imaging Cherenkov detectorPartícules (Física nuclear)High Energy Physics - ExperimentPHYSICSHigh Energy Physics - Experiment (hep-ex)Ionization0103 physical sciencesCHARGED-PARTICLES; SUPERSYMMETRY; PHYSICS; LEP[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsNuclear ExperimentSUPERSYMMETRYCherenkov radiationDELPHIPhysicsTime projection chamber010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyCharge (physics)LEPLARGE ELECTRON POSITRON COLLIDERCharged particleCHARGED-PARTICLESPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIPARTICLE PHYSICSFísica nuclearHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Improved measurements of cross sections and asymmetries at the Z0 resonance

1994

During the 1992 running period of the LEP e+e- collider, the DELPHI experiment accumulated approximately 24 pb-1 of data at the Z0 peak. The decays into hadrons and charged leptons have been analysed to give values for the cross sections and leptonic forward-backward asymmetries which are significantly improved with respect to those previously published by the DELPHI collaboration. Incorporating these new data, more precise values for the Z0 resonance parameters are obtained from model-independent fits. The results are interpreted within the framework of the Standard Model, yielding for the top quark mass m(t) = 157(-48)+36(expt.)-20(+19)(Higgs) GeV, and for the effective mixing angle sin2 …

Nuclear and High Energy PhysicsParticle physicsTop quarkLUND MONTE-CARLOElectron–positron annihilationLEP-SLC ENERGIESElementary particle7. Clean energy01 natural sciencesJET FRAGMENTATIONStandard ModelPHYSICSNuclear physicsBHABHA SCATTERINGParticle decay0103 physical sciencesPROGRAM[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]RADIATIVE-CORRECTIONSZ0010306 general physicsDELPHIPhysicsLOWEST-ORDER CALCULATIONScross section010308 nuclear & particles physicsDELPHI; Bhabha scattering; cross section; Z0High Energy Physics::PhenomenologyLARGE ELECTRON POSITRON COLLIDERLUND MONTE-CARLO; ELECTRON-POSITRON COLLISIONS; LOWEST-ORDER CALCULATIONS; LEP-SLC ENERGIES; BHABHA SCATTERING; RADIATIVE-CORRECTIONS; JET FRAGMENTATION; PROGRAM; PHYSICSPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHILarge Electron–Positron ColliderHiggs bosonPARTICLE PHYSICSFísica nuclearHigh Energy Physics::ExperimentELECTRON-POSITRON COLLISIONSParticle Physics - ExperimentLepton
researchProduct

Study of Large Hemispherical Photomultiplier Tubes for the ANTARES Neutrino Telescope

2005

The ANTARES neutrino telescope, to be immersed depth in the Mediterranean Sea, will consist of a 3 dimensional matrix of 900 large area photomultiplier tubes housed in pressure resistant glass spheres. The selection of the optimal photomultiplier was a critical step for the project and required an intensive phase of tests and developments carried out in close collaboration with the main manufacturers worldwide. This paper provides an overview of the tests performed by the collaboration and describes in detail the features of the PMT chosen for ANTARES.

Nuclear and High Energy PhysicsPhotomultiplierPhysics - Instrumentation and DetectorsNeutrino detectionNeutrino telescopeFOS: Physical sciences01 natural scienceslarge area photosensor hemispherical photomultiplier neutrino detectionNuclear physicsOpticsIntensive Phase0103 physical sciences14. Life underwater[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]010306 general physicsInstrumentationAstroparticle physicsPhysics010308 nuclear & particles physicsbusiness.industryHemispherical photomultiplierInstrumentation and Detectors (physics.ins-det)Large area photosensorGlass spheresNeutrino detector95.55.Vj; 85.60.HaFísica nuclearbusinesshemispherical photomultiplier; large area photosensor; neutrino detection
researchProduct

Cultural institutions as agents of urban and community regeneration in the (post-)pandemic city. The case of the «Laboratorio Zen Insieme» in Palermo

2022

Although all cities in the world have been affected by the COVID-19 pandemic, its impacts on the territories, yet to be understood, are unevenly distributed, revealing extremely varied imbalances depending on the places. However, it is clear that the virus and its variants have aggravated pre-existing socio-spatial inequalities, creating new ones and bringing attention back to those implications between space, planning, public health and citizenship that are at the origins of contemporary urbanism. In a reference framework in which the crisis is globalized but unequal and in the absence of a welfare system capable of responding to the urgencies of the most marginalized social contexts and g…

Olsen 2018Settore ICAR/21 - UrbanisticaSettore M-GGR/01 - GeografiaSacco and Blessi 2009). In the current (post-) pandemic context and through the lens of a southern European perspective the purpose of this article is to critically reflect about the role of culture as possible vehicle of urban and community regeneration. In particular we will focus on the activities of the no profit organization «Laboratorio Zen Insieme» in ZEN2 one of the last large popular and peripheral neighborhoods built in Palermo at the end of 80s in order to explore and understand how cultural practices work as agent of urban and social transformation capable of addressing emerging issues especially in the pandemic scenario we are experiencing. Thecasestudy has been conducted through analysis of documents participative observations (Honer and Hitzler 2015) and qualitative in-depth interviews with key actors involved in the conception organization and management of the activities carried out by Laboratorio Zen Insieme with representatives of local institutions and non-formal conversations with participants of the workshops heldin the neighborhood. The experience we narrate finds that cultural practices have re-conceptualized their design and functions as strategies of urban and community regeneration and at the same time have contributed to answer to emergent issues in developing proximity and local based strategies facing up to problems inherent civil rights educationalpoverty socio-spatial justice and have changed the image and identity of urban places they inhabit.In this sense the research provides a framework for development of strategies and legitimization for cultural practices and a point of discussionabouttheirrolein urban development.Although all cities in the world have been affected by the COVID-19 pandemic its impacts on the territories yet to be understood are unevenly distributed revealing extremely varied imbalances depending on the places. However it is clear that the virus and its variants have aggravated pre-existing socio-spatial inequalities creating new ones and bringing attention back to those implications between space planning public health and citizenship that are at the origins of contemporary urbanism. In a reference framework in which the crisis is globalized but unequal and in the absence of a welfare system capable of responding to the urgencies of the most marginalized social contexts and groups a response to the new social and individual needs has been offered by cultural institutions that play a role of territorial agency often independently or in the absence of political institutions. Far from the idea of entertainment and divertissement it is in fact increasingly clear how the practices of cultural innovation experimenting with various forms of action and participation can in some cases play a fundamental role in the processes of social cohesion and community building representing an antidote to the worsening of the phenomena of marginalization and socio-spatial inequalities within cities and territories (Colantonio and Dixon 2011
researchProduct

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer p…

2011

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabDose-dense chemotherapyAdenocarcinomaNSCLCAntibodies Monoclonal HumanizedDrug Administration ScheduleInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsDose/dense-metronomic-chemotherapymedicineHumansLung cancerAgedEtoposideNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerAntibodies MonoclonalmPEBev regimenMiddle Agedmedicine.diseaseVEGFBevacizumabRegimenOncologyToxicityCarcinoma Squamous CellMolecular MedicineEvery Three WeeksCarcinoma Large CellFemaleCisplatinbusinessmedicine.drugCancer biologytherapy
researchProduct

Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

2015

Abstract Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported. Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944,…

OncologyAdultMalemedicine.medical_specialtyEpidemiologyChronic lymphocytic leukemiamedicine.medical_treatmentFollicular lymphomaBiologyArticleBody Mass IndexYoung Adultimmune system diseasesRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseLymphangiogenesisAdiposityAgedRetrospective StudiesPolymorphism GeneticAbsolute risk reductionDNA NeoplasmMiddle Agedmedicine.diseaseObesityLymphomaCytokineOncologyIL1AImmunologyCytokinesFemaleLymphoma Large B-Cell DiffuseBody mass indexCancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
researchProduct

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

2020

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicineAntibodies BispecificmedicineHumansComplete responsebusiness.industryLymphoma Non-HodgkinHematologymedicine.diseaseLymphomaOncology030220 oncology & carcinogenesisRelapsed refractoryBlinatumomabLymphoma Large B-Cell DiffuseNeoplasm Recurrence LocalbusinessDiffuse large B-cell lymphoma030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma

2022

Abstract Background: Information about the long-term tolerability of tafasitamab is still limited. Methods: 5 of 92 patients treated within a phase IIa study of single-agent tafasitamab in relapsed or refractory B NHL were followed for up to five years or longer for long-term tolerability. Results: Treatment was very well tolerated in an outpatient setting with no hospitalizations needed and mild and tolerable adverse events that occurred mostly within the first two years of treatment. Conclusions: Given the excellent tolerability and efficacy of tafasitamab this agent can be used to induce remission in relapsed or refractory lymphoma either alone or in combination with chemotherapy.

OncologyCancer Researchmedicine.medical_specialtyChemotherapybiologybusiness.industryAnti cd19medicine.medical_treatmentAntigens CD19CancerHematologyImmunotherapyAntibodies Monoclonal Humanizedmedicine.diseaseOncologyTolerabilityRefractoryInternal medicinebiology.proteinHumansMedicineLymphoma Large B-Cell DiffuseAntibodybusinessAdverse effectClinical Lymphoma Myeloma and Leukemia
researchProduct

MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURAB…

2021

OncologyCancer Researchmedicine.medical_specialtyOncologybusiness.industryInternal medicineFirst linemedicineHematologyGeneral Medicinebusinessmedicine.diseaseDiffuse large B-cell lymphomaHematological Oncology
researchProduct

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Adva…

2012

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms …

OncologyMaleerlotinibLung NeoplasmsHealth-related quality of lifeNSCLCchemotherapyDeoxycytidinelaw.inventionRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsSurveys and QuestionnaireQuality of life analysis of TORCHErlotinib HydrochloridePrognosishumanitiesOncologyResearch DesignAdvanced non–small-cell lung cancerCarcinoma Squamous CellFemaleErlotinibRandomized trialmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiEGFRFirst-line treatmentfirst-line erlotinibsecond-line cisplatin/gemcitabine chemotherapyAdenocarcinomaNOFollow-Up StudieErlotinib HydrochlorideInternal medicineadvanced non-small-cell lung cancermedicineHumansLung cancerAdvanced non-small-cell lung cancer; Chemotherapy; EGFR; Erlotinib; First-line treatment; Health-related quality of life; Randomized trialQuality of life analysis of TORCH first-line erlotinib second-line cisplatin/gemcitabine chemotherapy advanced non-small-cell lung cancer.AgedNeoplasm StagingSalvage TherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryQuestionnaireCancerQuinazolinemedicine.diseaseInterim analysisGemcitabineGemcitabineSurgeryLung Neoplasmquality of lifeQuinazolinesCarcinoma Large CellCisplatinNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct